ClinicalTrials.gg
TerminatedNCT01375374VICTORUpdated Aug 28, 2017Results posted

Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide

A Phase 3 interventional study of Lacosamide and Levetiracetam in Epilepsy, Partial, sponsored by UCB Pharma. Terminated at 7 sites in 3 countries. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-08-28.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Slow progress despite recruitment boosting efforts e.g., expert advice obtained from leading study center Investigators; decision thus made to terminate.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing lacosamide in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Lacosamide · Epilepsies, Partial.

Enrollment
11th of 11
11 · median 100
Started
2011
the only one that year
Phase 3
4 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
5 of 11
UCB Pharma

Among the 11 studies testing lacosamide in Epilepsies, Partial, this one is the 11th largest by enrollment, is the only one that started in 2011, is one of 4 in phase 3, and was the 10th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 11 studies testing lacosamide in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About lacosamide

Lacosamide: first FDA approval 2008 (VIMPAT), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 45 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing lacosamide in Epilepsies, Partial as a file.
02

Study summary

The purpose of the trial is to investigate whether changes in lipids and hormonal parameters can be observed in blood when Carbamazepine treatment is replaced with Lacosamide treatment, while Levetiracetam treatment remains unchanged.

03

Conditions studied

  • Epilepsy, Partial

Keywords

  • Vimpat
  • Partial seizures
  • Carbamazepine
  • Hormone levels
  • Lipid levels
  • Lacosamide
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subject with diagnosis of Epilepsy with Partial-Onset Seizures
  • Subject only taking Levetiracetam in combination with Carbamazepine as adjunctive treatment for Epilepsy

Exclusion criteria

Exclusion Criteria:

  • Subject is taking another Anti-Epileptic Drug (AED) than Carbamazepine (CBZ) and Levetiracetam (LEV)
  • Subject is taking lipid lowering agents
  • Subject is taking enzyme inducers
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Lacosamide

    commercial 50 mg (pinkish) and 100 mg (yellow) tablets

    Drug: Lacosamide · Drug: Levetiracetam

Interventions

  • 4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.

    Also known as: Vimpat

  • Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.

    Also known as: Keppra

06

What researchers measure

Primary outcomes

  1. Change in Serum Sex Hormone Binding Globulin (SHBG) From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)

    Due to premature termination of enrollment prior to achieving the planned sample size (a total of 28 subjects), this primary safety variable was assessed for descriptive purposes only. A negative value indicates an improvement.

    Time frame: From Day 1 (Baseline) to Day 84 (Treatment Period End)

Secondary outcomes

  1. Change in Sex Hormone Calculated Free Androgen Index Levels From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)

    The change in sex hormone calculated free androgen index (100 x Testosterone/sex hormone binding globulin) levels from Baseline to the end of Maintenance Period was summarized descriptively by visit. A negative value indicates an improvement.

    Time frame: From Day 1 (Baseline) to Day 84 (Treatment Period End)

  2. Change in Serum Thyroid Hormone Free Thyroxine Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)

    The change in the serum thyroid hormone free thyroxine level from Baseline to the end of the Maintenance Period was summarized descriptively by visit.

    Time frame: From Day 1 (Baseline) to Day 84 (Treatment Period End)

  3. Change in Total Cholesterol Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)

    The change in total cholesterol levels from Baseline to the end of the Maintenance Period was summarized descriptively by visit. A negative value indicates an improvement.

    Time frame: From Day 1 (Baseline) to Day 84 (Treatment Period End)

07

Results

Posted Nov 26, 2014
Limitations and caveats
The results of this study are limited due to the small sample size.

Participant flow

The study was conducted at 5 sites across Austria (1 site), Germany (3 sites), and Spain (1 site).

Participant flow — Overall Study
MilestoneLacosamide
Started11
Completed10
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryChange in Serum Sex Hormone Binding Globulin (SHBG) From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)

Due to premature termination of enrollment prior to achieving the planned sample size (a total of 28 subjects), this primary safety variable was assessed for descriptive purposes only. A negative value indicates an improvement.

Time frame:
From Day 1 (Baseline) to Day 84 (Treatment Period End)
Reported as:
Median · nmol/L
Change in Serum Sex Hormone Binding Globulin (SHBG) From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)
nmol/LLacosamide
Change in Serum Sex Hormone Binding Globulin (SHBG) From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)-12.80 (-20.3 to 4.9)
SecondaryChange in Sex Hormone Calculated Free Androgen Index Levels From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)

The change in sex hormone calculated free androgen index (100 x Testosterone/sex hormone binding globulin) levels from Baseline to the end of Maintenance Period was summarized descriptively by visit. A negative value indicates an improvement.

Time frame:
From Day 1 (Baseline) to Day 84 (Treatment Period End)
Reported as:
Median · Free Androgen Index
Change in Sex Hormone Calculated Free Androgen Index Levels From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)
Free Androgen IndexLacosamide
Change in Sex Hormone Calculated Free Androgen Index Levels From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)9.493 (2.39 to 26.46)
SecondaryChange in Serum Thyroid Hormone Free Thyroxine Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)

The change in the serum thyroid hormone free thyroxine level from Baseline to the end of the Maintenance Period was summarized descriptively by visit.

Time frame:
From Day 1 (Baseline) to Day 84 (Treatment Period End)
Reported as:
Median · pmol/L
Change in Serum Thyroid Hormone Free Thyroxine Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)
pmol/LLacosamide
Change in Serum Thyroid Hormone Free Thyroxine Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)2.70 (1.5 to 5.5)
SecondaryChange in Total Cholesterol Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)

The change in total cholesterol levels from Baseline to the end of the Maintenance Period was summarized descriptively by visit. A negative value indicates an improvement.

Time frame:
From Day 1 (Baseline) to Day 84 (Treatment Period End)
Reported as:
Median · mmol/L
Change in Total Cholesterol Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)
mmol/LLacosamide
Change in Total Cholesterol Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)-0.540 (-1.46 to 0.11)

Adverse events

Collected over Treatment Emergent Adverse Event were reported from Baseline until the Safety Follow-up Visit (two weeks after end of Treatment Period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lacosamide—0/11 (0%)5/11 (45.5%)
Most frequent other events
Most frequent other events
EventLacosamide
FatigueGeneral disorders1/11
BronchitisInfections and infestations1/11
InfluenzaInfections and infestations1/11
ConvulsionNervous system disorders1/11
Disturbance in attentionNervous system disorders1/11
ParaesthesiaNervous system disorders1/11
Partial seizuresNervous system disorders1/11
TremorNervous system disorders1/11
AggressionPsychiatric disorders1/11
Hot flushVascular disorders1/11

Baseline characteristics

The Baseline Analysis Population refers to the Safety Set (SS). The SS consists of all patients who received at least 1 dose of Lacosamide.

Age, Continuous
Age, Continuous(years)Lacosamide
Mean31.5 ± 5.9
Age, Categorical
Age, Categorical(Participants)Lacosamide
<=18 years0
Between 18 and 65 years11
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Lacosamide
Female0
Male11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lacosamide
American Indian or Alaska Native1
Asian0
Black or African American0
Native Hawaiin or other Pacific Islander0
White9
Other/Mixed1
Weight
Weight(kilograms)Lacosamide
Mean82.81 ± 16.25
Height
Height(centimeters)Lacosamide
Mean178.05 ± 10.14
Body Mass Index
Body Mass Index(kilogram per square meter)Lacosamide
Mean25.89 ± 3.01
08

Study locations

7 sites
  • 11
    Innsbruck, Austria
  • 12
    Salzburg, Austria
  • 2
    Bielefeld, Germany
  • 1
    Bonn, Germany
  • 5
    Erlangen, Germany
  • 22
    Alcorcon, Spain
  • 20
    Santiago de Compostela, Spain
09

References and documents

Publications

  • Elger CE, Rademacher M, Brandt C, Elmoufti S, Dedeken P, Eckhardt K, Tennigkeit F, De Backer M. Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: A small phase IIIb, prospective, multicenter, open-label trial. Epilepsy Behav. 2016 Sep;62:1-5. doi: 10.1016/j.yebeh.2016.05.023. Epub 2016 Jul 15. PubMed 27423106 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year 8 months after primary completion. A results delay was requested in Dec 2013.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2011
First posted
Jun 17, 2011
Start
Jul 2011
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results delay requested
Dec 13, 2013
Results first posted
Nov 26, 2014
Last update
Aug 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01375374
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jun 17, 2011
Start date
Jul 2011
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Nov 26, 2014
Last update
Aug 28, 2017

Study contacts

UCB Cares
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lacosamide · Levetiracetam

Start the discussion